Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D

Basit Öğe Kaydı
dc.authorid0000-0003-2137-7934en_US
dc.authorid0000-0003-2178-3182en_US
dc.authorid0000-0001-6103-5336en_US
dc.contributor.authorAnastasiou, Olympia E.
dc.contributor.authorCaruntu, Florin A.
dc.contributor.authorCurescu, Manuela G.
dc.contributor.authorYalçın, Kendal
dc.contributor.authorAkarca, Ulus S.
dc.contributor.authorGürel, Selim
dc.contributor.authorÇelen, Mustafa Kemal
dc.date.accessioned2024-03-25T08:31:57Z
dc.date.available2024-03-25T08:31:57Z
dc.date.issued2024en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.description.abstractBackground & Aims: Until recently, pegylated interferon-alfa-2a (PEG-IFNa) therapy was the only treatment option for patients infected with hepatitis D virus (HDV). Treatment with PEG-IFNa with or without tenofovir disoproxil fumarate (TDF) for 96 weeks resulted in HDV RNA suppression in 44% of patients at the end of therapy but did not prevent short-term relapses within 24 weeks. The virological and clinical long-term effects after prolonged PEG-IFNa-based treatment of hepatitis D are unknown. Methods: In the HIDIT-II study patients (including 40% with liver cirrhosis) received 180 μg PEG-IFNa weekly plus 300 mg TDF once daily (n = 59) or 180 μg PEG-IFNa weekly plus placebo (n = 61) for 96 weeks. Patients were followed until week 356 (5 years after end of therapy). Results: Until the end of follow-up, 16 (13%) patients developed liver-related complications (PEG-IFNa + TDF, n = 5 vs PEG-IFNa + placebo, n = 11; p =.179). Achieving HDV suppression at week 96 was associated with decreased long-term risk for the development of hepatocellular carcinoma (p =.04) and hepatic decompensation (p =.009). Including complications irrespective of PEG-IFNa retreatment status, the number of patients developing serious complications was similar with (3/18) and without retreatment with PEG-IFNa (16/102, p >.999) but was associated with a higher chance of HDV-RNA suppression (p =.024, odds ratio 3.9 [1.3–12]). Conclusions: Liver-related clinical events were infrequent and occurred less frequently in patients with virological responses to PEG-IFNa treatment. PEG-IFNa treatment should be recommended to HDV-infected patients until alternative therapies become available. Retreatment with PEG-IFNa should be considered for patients with inadequate response to the first course of treatment. Clinical Trial registration: NCT00932971.en_US
dc.identifier.citationAnastasiou, O. E., Caruntu, F. A., Curescu, M. G., Yalçın, K., Akarca, U. S., Gürel, S. ve diğerleri. (2024). Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D. Liver International, 44(1), 139-147.en_US
dc.identifier.doi10.1111/liv.15745
dc.identifier.endpage147en_US
dc.identifier.issn1478-3223
dc.identifier.issue1en_US
dc.identifier.pmid37787009
dc.identifier.scopus2-s2.0-85173433341
dc.identifier.scopusqualityQ1
dc.identifier.startpage139en_US
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.15745
dc.identifier.urihttps://hdl.handle.net/11468/13690
dc.identifier.volume44en_US
dc.identifier.wosWOS:001079543600001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYalçın, Kendal
dc.institutionauthorÇelen, Mustafa Kemal
dc.language.isoenen_US
dc.publisherJohn Wiley and Sons Incen_US
dc.relation.ispartofLiver International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHDVen_US
dc.subjectHIDIT-IIen_US
dc.subjectInterferonen_US
dc.subjectLong-term outcomeen_US
dc.subjectNUCen_US
dc.titleFive-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis Den_US
dc.titleFive-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.pdf
Boyut:
470.13 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu